Inotodiol as agonist of liver x receptors, and use thereof
The present disclosure relates to inotodiol as a liver X receptor agonist and use thereof for the treatment of a liver X receptor-mediated disease. Inotodiol according to an aspect, or a prodrug thereof has LXRβ-specific agonist activity, and thus not only has remarkable safety compared to other LXR agonists, but can also be effectively used in the treatment of LXR-related diseases, such as a neurodegenerative brain disease, an autoimmune disease, NASH, and NAFLD.
1 . A method of treating Alzheimer's disease or rheumatoid arthritis, the method comprising administering inotodiol or a prodrug thereof to a subject in need thereof,
wherein the prodrug is inotodiol-acetate diester, inotodiol-butyrate diester, inotodiol-caprylate diester or inotodiol-myristate diester, and
the inotodiol or the prodrug thereof is a LXR agonist that upregulates the expression or activity of the LXR.
2 . The method of claim 1 , wherein the prodrug is inotodiol-butyrate diester.
3 . The method of claim 1 , wherein the prodrug is inotodiol-caprylate diester.
4 . The method of claim 1 , wherein the prodrug is inotodiol-myristate diester.
5 . The method of claim 1 , wherein the prodrug is inotodiol-acetate diester.